JP2018514523A - リボシクリブ錠剤 - Google Patents

リボシクリブ錠剤 Download PDF

Info

Publication number
JP2018514523A
JP2018514523A JP2017553915A JP2017553915A JP2018514523A JP 2018514523 A JP2018514523 A JP 2018514523A JP 2017553915 A JP2017553915 A JP 2017553915A JP 2017553915 A JP2017553915 A JP 2017553915A JP 2018514523 A JP2018514523 A JP 2018514523A
Authority
JP
Japan
Prior art keywords
ribocyclib
tablet
tablets
core
succinate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017553915A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018514523A5 (enExample
Inventor
グルラジャン，ビンドゥーマドハーヴァン
グランドゥリ，アルノー
コスタ，ルイ
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2018514523(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2018514523A publication Critical patent/JP2018514523A/ja
Publication of JP2018514523A5 publication Critical patent/JP2018514523A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017553915A 2015-04-16 2016-04-14 リボシクリブ錠剤 Pending JP2018514523A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562148240P 2015-04-16 2015-04-16
US62/148,240 2015-04-16
PCT/IB2016/052136 WO2016166703A1 (en) 2015-04-16 2016-04-14 Ribociclib tablet

Publications (2)

Publication Number Publication Date
JP2018514523A true JP2018514523A (ja) 2018-06-07
JP2018514523A5 JP2018514523A5 (enExample) 2019-05-23

Family

ID=55806565

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017553915A Pending JP2018514523A (ja) 2015-04-16 2016-04-14 リボシクリブ錠剤

Country Status (31)

Country Link
US (6) US10799506B2 (enExample)
EP (3) EP3283058B1 (enExample)
JP (1) JP2018514523A (enExample)
KR (2) KR102750931B1 (enExample)
CN (2) CN107530292B (enExample)
AR (1) AR104257A1 (enExample)
AU (5) AU2016248017A1 (enExample)
BR (1) BR112017021283A2 (enExample)
CA (1) CA2982425C (enExample)
CL (1) CL2017002593A1 (enExample)
CO (1) CO2017010510A2 (enExample)
DK (2) DK4197530T3 (enExample)
EA (1) EA201792290A1 (enExample)
EC (1) ECSP17075052A (enExample)
ES (2) ES2938261T3 (enExample)
FI (2) FI4197530T3 (enExample)
HR (2) HRP20230053T1 (enExample)
HU (1) HUE061213T2 (enExample)
IL (2) IL254818B1 (enExample)
LT (1) LT4197530T (enExample)
MX (1) MX2017013350A (enExample)
PE (1) PE20180035A1 (enExample)
PH (1) PH12017501820A1 (enExample)
PL (2) PL4197530T3 (enExample)
PT (2) PT4197530T (enExample)
RS (1) RS67697B1 (enExample)
SG (1) SG11201708084PA (enExample)
SI (2) SI4197530T1 (enExample)
TN (1) TN2017000422A1 (enExample)
TW (1) TW201642864A (enExample)
WO (1) WO2016166703A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023543565A (ja) * 2020-09-29 2023-10-17 ラボラトリオス シラネス、エセ．ア．デ セ．べ． 脂質異常症及び心血管疾患の処置及び予防のためのスタチン類及びフィブラート類の薬学的配合物

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4772247A2 (en) 2013-08-14 2026-07-08 Novartis AG Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer
SI4197530T1 (sl) * 2015-04-16 2026-03-31 Novartis Ag Tableta ribocikliba
CA3048036A1 (en) 2018-07-02 2020-01-02 Apotex Inc Crystalline form of ribociclib succinate
WO2021041348A1 (en) 2019-08-26 2021-03-04 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
IL293940B2 (en) 2019-12-16 2026-05-01 Lunella Biotech Inc Selective cancer drugs CDK4/6 inhibitors
EP4077325B1 (en) 2019-12-16 2026-03-11 Lunella Biotech, Inc. Selective cdk4/6 inhibitor cancer therapeutics
WO2022029798A1 (en) * 2020-08-03 2022-02-10 Natco Pharma Limited Pharmaceutical compositions comprising ribociclib
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
CN117396208A (zh) 2021-07-16 2024-01-12 达纳－法伯癌症研究所公司 细胞周期蛋白依赖性激酶4/6(cdk4/6)和ikzf2(helios)的小分子降解剂及其使用方法
TWI908143B (zh) 2022-01-25 2025-12-11 瑞士商諾華公司 瑞博西尼藥物組成物用於治療癌症之用途
WO2024049926A1 (en) 2022-08-31 2024-03-07 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof
JP2026513185A (ja) 2023-03-27 2026-04-23 ノバルティス アーゲー アロマターゼ阻害薬との組み合わせでのリボシクリブによる早期乳癌の治療方法
US20250319032A1 (en) 2024-04-15 2025-10-16 Novartis Ag Pharmaceutical compositions of ribociclib
WO2026128391A1 (en) 2024-12-09 2026-06-18 Arvinas Operations, Inc. Combinations of vepdegestrant and cdk4/6 inhibitors for treating esr1-mutant breast cancer

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5428812A (en) * 1977-08-09 1979-03-03 Yoshitomi Pharmaceut Ind Ltd Preparation of coated tablet
JP2013542257A (ja) * 2010-11-10 2013-11-21 ノバルティス アーゲー ７−シクロペンチル−２−（５−ピペラジン−１−イル−ピリジン−２−イルアミノ）−７ｈ−ピロロ［２，３−ｄ］ピリミジン−６−カルボン酸ジメチルアミドの塩およびその製造方法
JP2014505095A (ja) * 2011-02-11 2014-02-27 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
EP2742940A1 (en) * 2012-12-13 2014-06-18 IP Gesellschaft für Management mbH Salts of aza-bicyclo-di-aryl ethers for adminstration once daily, twice daily or thrice daily
WO2014097125A1 (en) * 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib
WO2014147573A2 (en) * 2013-03-21 2014-09-25 Novartis Ag Combination therapy
WO2014195421A1 (en) * 2013-06-06 2014-12-11 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9414045D0 (en) 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
EP0771339B1 (en) * 1994-07-12 2003-10-15 BPSI Holdings, Inc. Dry moisture barrier film coating composition, method of coating substrates using the same and pharmaceutical tablets coated therewith
US6448323B1 (en) * 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
US8784781B2 (en) * 2009-09-24 2014-07-22 Mcneil-Ppc, Inc. Manufacture of chewing gum product with radiofrequency
CU20090172A7 (es) * 2009-10-09 2011-10-05 Ct De Investigación Y Desarrollo De Medicamentos Sistemas tricíclicos y tetracíclicos con actividad sobre el sistema nervioso central y vascular
EP3733170A1 (en) * 2012-07-13 2020-11-04 Oncternal Therapeutics, Inc. A method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms)
SI4197530T1 (sl) * 2015-04-16 2026-03-31 Novartis Ag Tableta ribocikliba
CN109953966A (zh) * 2017-12-26 2019-07-02 天津耀辰实业发展有限公司 一种含有瑞博西尼的药物组合物及其制备方法
JP7347388B2 (ja) 2020-09-25 2023-09-20 信越化学工業株式会社 紫外線硬化型有機変性シリコーン組成物および硬化物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5428812A (en) * 1977-08-09 1979-03-03 Yoshitomi Pharmaceut Ind Ltd Preparation of coated tablet
JP2013542257A (ja) * 2010-11-10 2013-11-21 ノバルティス アーゲー ７−シクロペンチル−２−（５−ピペラジン−１−イル−ピリジン−２−イルアミノ）−７ｈ−ピロロ［２，３−ｄ］ピリミジン−６−カルボン酸ジメチルアミドの塩およびその製造方法
JP2014505095A (ja) * 2011-02-11 2014-02-27 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
EP2742940A1 (en) * 2012-12-13 2014-06-18 IP Gesellschaft für Management mbH Salts of aza-bicyclo-di-aryl ethers for adminstration once daily, twice daily or thrice daily
WO2014097125A1 (en) * 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib
WO2014147573A2 (en) * 2013-03-21 2014-09-25 Novartis Ag Combination therapy
WO2014195421A1 (en) * 2013-06-06 2014-12-11 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023543565A (ja) * 2020-09-29 2023-10-17 ラボラトリオス シラネス、エセ．ア．デ セ．べ． 脂質異常症及び心血管疾患の処置及び予防のためのスタチン類及びフィブラート類の薬学的配合物

Also Published As

Publication number Publication date
BR112017021283A2 (en) 2018-06-26
US12064434B2 (en) 2024-08-20
CN107530292B (zh) 2022-11-01
WO2016166703A1 (en) 2016-10-20
FI4197530T3 (fi) 2026-02-03
PH12017501820A1 (en) 2018-04-23
CA2982425C (en) 2023-10-31
US20230104792A1 (en) 2023-04-06
ECSP17075052A (es) 2018-02-28
US20250127785A1 (en) 2025-04-24
US20200390771A1 (en) 2020-12-17
CN115554257A (zh) 2023-01-03
EA201792290A1 (ru) 2018-02-28
AR104257A1 (es) 2017-07-05
EP4620458A2 (en) 2025-09-24
AU2022215155A1 (en) 2022-09-01
PT3283058T (pt) 2023-02-03
AU2022215155B2 (en) 2024-08-01
SI4197530T1 (sl) 2026-03-31
AU2019201929B2 (en) 2020-07-09
AU2016248017A1 (en) 2017-10-19
PT4197530T (pt) 2026-02-05
IL254818A0 (en) 2017-12-31
SG11201708084PA (en) 2017-10-30
TN2017000422A1 (en) 2019-01-16
PL4197530T3 (pl) 2026-03-23
AU2020250190A1 (en) 2020-11-05
EP4620458A3 (en) 2025-10-22
PE20180035A1 (es) 2018-01-09
KR102750931B1 (ko) 2025-01-09
MX2017013350A (es) 2018-01-25
KR20170137101A (ko) 2017-12-12
DK3283058T3 (da) 2023-02-13
TW201642864A (zh) 2016-12-16
CA2982425A1 (en) 2016-10-20
IL327430A (en) 2026-05-01
IL254818B1 (en) 2026-05-01
CN107530292A (zh) 2018-01-02
ES2938261T3 (es) 2023-04-05
HRP20230053T1 (hr) 2023-03-03
ES3062263T3 (en) 2026-04-09
CO2017010510A2 (es) 2018-03-20
US12419894B2 (en) 2025-09-23
US20180071292A1 (en) 2018-03-15
PL3283058T3 (pl) 2023-03-20
SI3283058T1 (sl) 2023-03-31
LT4197530T (lt) 2026-02-25
EP4197530B1 (en) 2025-11-12
EP3283058A1 (en) 2018-02-21
US20250134893A1 (en) 2025-05-01
HUE061213T2 (hu) 2023-05-28
HRP20260123T1 (hr) 2026-03-13
EP4197530A1 (en) 2023-06-21
AU2024227794A1 (en) 2024-11-21
RS67697B1 (sr) 2026-02-27
FI3283058T3 (fi) 2023-03-01
US20250090531A1 (en) 2025-03-20
CL2017002593A1 (es) 2018-05-18
AU2019201929A1 (en) 2019-04-11
US10799506B2 (en) 2020-10-13
DK4197530T3 (da) 2026-02-09
KR20250009572A (ko) 2025-01-17
EP3283058B1 (en) 2022-11-16

Similar Documents

Publication Publication Date Title
US12419894B2 (en) Ribociclib tablet
JP6402191B2 (ja) コリンアルホスセラートを含有するフィルムコーティング錠剤およびその製造方法
JP2024009815A (ja) アキシチニブを含有する医薬組成物
HK40089304A (en) Ribociclib tablet
TW202408531A (zh) 包含葡萄糖酸內酯之哌柏西利製劑
JP2020090464A (ja) ゾピクロン、その光学異性体又はこれらの塩の何れかを有効成分として含有する錠剤
KR101578627B1 (ko) 실로도신의 용출 특성이 향상된 약제학적 제제
EA042324B1 (ru) Таблетка, содержащая рибоциклиб
HK1243319B (en) Ribociclib tablet
HK1243319A1 (en) Ribociclib tablet
TWI726978B (zh) 一種含有喹啉衍生物或其鹽的藥物組成物
JP6673798B2 (ja) カペシタビンを有効成分とするフィルムコート医薬製剤
JP2026044274A (ja) パルボシクリブ錠剤
JP6293850B1 (ja) 医薬組成物におけるアジルサルタンの速やかな溶出性を維持し、かつ安定化する方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190415

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200303

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201027